Hikma Pharmaceuticals PLC (FRA:H5P)
€ 22 0.4 (1.85%) Market Cap: 4.89 Bil Enterprise Value: 5.78 Bil PE Ratio: 27.25 PB Ratio: 2.33 GF Score: 89/100

Full Year 2021 Hikma Pharmaceuticals PLC Earnings Call - Q&A Session Transcript

Feb 24, 2022 / 09:30AM GMT
Release Date Price: €22.8 (-2.56%)
Sigurdur Oli Olafsson
Hikma Pharmaceuticals PLC - CEO & Executive Director

So good morning, everybody. Welcome to the people here in the room. You made it through the weather to visit our office. So it's great to see people face-to-face. And also, welcome to the people on the line.

We are very pleased to talk to you today both from a personal point of view of seeing people face-to-face for the first time in 2 years, but secondly, to talk about the great results that we had in 2021.

I'm not going to go through the results. I think you saw the press release and you have the presentation this morning. A strong growth in all 3 businesses in 2021. A lot of new launches, many business development deals. A challenging environment still in the U.S. But overall, I think the performance was really, really good in all 3 businesses, and a strong guidance for 2022.

So with that, I was just going to open it up for question and answer, and maybe we start in the room here. And then, of course, we go online a little bit later on when we are running out of questions in the room. So who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot